UNSPSC 51431904: Candesartan cilexetil

This classification denotes an angiotensin ii receptor antagonist with the molecular formula C33H34N6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R85M2X0D68, chemically known as 1h-benzimidazolium, 7-carboxy-1-(2-((cyclohexylcarbonyl)oxy)ethyl)-2-ethoxy-1-(2-(1h-tetrazol-5-yl)(1,1-biphenyl)-4-yl)-, hydroxide, inner salt, (+-)- but more generally known as candesartan cilexetil, which bears US NIH Compound Identifier 2540.

UNSPSC 51431904 Candesartan cilexetil is a Commodity code covering a specific antihypertensive pharmaceutical. State and local governments buy this drug through two distinct procurement channels: direct procurement by public safety agencies for emergency medical services and formulary-level procurement by health and human services departments through cooperative purchasing agreements and state pharmacy benefit programs. Recent solicitations show government buyers acquiring both individual medications (including this class of agent) alongside other emergency pharmaceuticals and positioning themselves to source branded and generic pharmaceuticals directly from manufacturers or through authorized wholesalers under multi-year agreements.

Activity under this code spans state health agencies, municipal fire and rescue departments, and state-administered cooperative purchasing alliances. The City of Tampa's Purchasing Department issued an IFB (Solicitation 26P00188) in April 2026 for Advanced Life Support Medications for Tampa Fire Rescue in Hillsborough County, Florida—a $40,000 estimated-value contract for emergency cardiac and vasodilator agents with a one-year term and two optional one-year renewals, awarded to the lowest responsive bidder by June 2026 with a 5 percent Small Local Business Enterprise bid discount available. The Texas Health and Human Services Commission issued an RFI (HHS0017013) in March 2026 to explore direct-to-manufacturer pharmacy procurement models outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Multistate Cooperative Purchasing Alliance issued an RFP (S1070000015802, due March 26, 2026) to establish multi-award contracts for generic pharmaceuticals and OTC products across state and local facilities in Minnesota and Oregon, requiring manufacturers to supply through three authorized wholesalers with pricing weighted 75 percent in evaluation, a two-year initial term, and optional extensions through June 2028. Recent activity concentrates in Florida, Texas, and the Upper Midwest, with cooperative purchasing vehicles increasingly central to state and local pharmaceutical procurement strategy.